Intestinal lysozyme releases Nod2 ligand(s) to promote the intestinal mucosal adjuvant activity of cholera toxin

Differential Regulatory Effects of Probiotics on Bone Metabolism by the Status of Bone Health and Delivery Route

Probiotics are known to have favorable effects on human health. Nevertheless, probiotics are not always beneficial and can cause unintended adverse effects such as bacteremia and/or inflammation in immunocompromised patients. In the present study, we investigated the effects of probiotics on the regulation of bone metabolism under different health conditions and delivery routes. Intragastric administration of Lactiplantibacillus plantarum to ovariectomized mouse models for mimicking post-menopausal osteoporosis in humans substantially ameliorated osteoporosis by increasing bone and mineral density. In contrast, such effects did not occur in normal healthy mice under the same condition. Interestingly, however, intraperitoneal administration of L. plantarum induced bone destruction by increasing osteoclast differentiation and decreasing osteoblast differentiation. Furthermore, when L. plantarum was implanted into mouse calvarial bone, it potently augmented bone resorption. Concordantly, L. plantarum upregulated osteoclastogenesis and downregulated osteoblastogenesis in in vitro experiments. These results suggest that L. plantarum can have distinct roles in the regulation of bone metabolism depending on bone health and the delivery route.

Intestinal lysozyme1 deficiency alters microbiota composition and impacts host metabolism through the emergence of NAD+-secreting ASTB Qing110 bacteria

The intestine plays a pivotal role in nutrient absorption and host defense against pathogens, orchestrated in part by antimicrobial peptides secreted by Paneth cells. Among these peptides, lysozyme has multifaceted functions beyond its bactericidal activity. Here, we uncover the intricate relationship between intestinal lysozyme, the gut microbiota, and host metabolism. Lysozyme deficiency in mice led to altered body weight, energy expenditure, and substrate utilization, particularly on a high-fat diet. Interestingly, these metabolic benefits were linked to changes in the gut microbiota composition. Cohousing experiments revealed that the metabolic effects of lysozyme deficiency were microbiota-dependent. 16S rDNA sequencing highlighted differences in microbial communities, with ASTB_g (OTU60) highly enriched in lysozyme knockout mice. Subsequently, a novel bacterium, ASTB Qing110, corresponding to ASTB_g (OTU60), was isolated. Metabolomic analysis revealed that ASTB Qing110 secreted high levels of NAD+, potentially influencing host metabolism. This study sheds light on the complex interplay between intestinal lysozyme, the gut microbiota, and host metabolism, uncovering the potential role of ASTB Qing110 as a key player in modulating metabolic outcomes.

IMPORTANCE

The impact of intestinal lumen lysozyme on intestinal health is complex, arising from its multifaceted interactions with the gut microbiota. Lysozyme can both mitigate and worsen certain health conditions, varying with different scenarios. This underscores the necessity of identifying the specific bacterial responses elicited by lysozyme and understanding their molecular foundations. Our research reveals that a deficiency in intestinal lysozyme1 may offer protection against diet-induced obesity by altering bacterial populations. We discovered a strain of bacterium, ASTB Qing110, which secretes NAD+ and is predominantly found in lyz1-deficient mice. Qing110 demonstrates positive effects in both C. elegans and mouse models of ataxia telangiectasia. This study sheds light on the intricate role of lysozyme in influencing intestinal health.